Investors + Media

Investor Relations

Corporate Profile

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC(R) protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

NASDAQ: ARVN

Price
Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases
November 27, 2019
NEW HAVEN, Conn. , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the 31 st Annual
November 21, 2019
Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience NEW HAVEN, Conn. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that Laurie
November 6, 2019
NEW HAVEN, Conn. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of $22.00

Events + Presentations

Presentations
There are no presentations at this time.